Dermatology News and Research

Latest Dermatology News and Research

Solution for treating obesity-related diseases may reside in fat tissue

Researchers at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have shown that the quality – not just the quantity – of adipose, or fat, tissue is a significant contributing factor in the development of inflammation and vascular disease in obese individuals. The study, which is a special feature on the iPAD version of the Journal of the American College of Cardiology, provides compelling evidence that the answer to treating cardiovascular disease and other obesity-related disorders, such as type 2 diabetes and cancer, might be found in the adipose tissue itself.

7 Jul 2011

Dems to CMS: Hold firm on Medicaid 'MOE' requirements

Meanwhile, a Government Accountability Office report finds that, although most physicians still accept some new Medicaid or Children's Health Insurance Program patients, a majority of primary care docs say they have difficulty finding specialists to provide care for young low-income patients.

6 Jul 2011

Adipose tissue might serve as target for treating obesity-related disorders

Researchers at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have shown that the quality - not just the quantity - of adipose, or fat, tissue is a significant contributing factor in the development of inflammation and vascular disease in obese individuals.

5 Jul 2011

U-M offers tips to help understand FDA's new rules about sunscreen

The July 4 weekend is a time for barbequing, lounging poolside or just goofing off in the backyard. But it's important to practice good sun safety, stress dermatologists at the University of Michigan Health System.

1 Jul 2011

Academy opposes legislation to repeal indoor tanning tax

The American Academy of Dermatology Association (Academy) opposes recent legislation to repeal the federal 10 percent indoor tanning tax. Countless scientific studies continue to demonstrate clear and compelling evidence that tanning bed use increases the risk of developing all forms of skin cancer.

1 Jul 2011

Epigenetics affects whether or not stem cells differentiate

Adult stem cells and progenitor cells may not come with a clean genetic slate after all. That's because a new report in the FASEB Journal shows that adult stem or progenitor cells have their own unique "epigenetic signatures," which change once a cell differentiates. This is important because epigenetic changes do not affect the actual make up in a cell's DNA, but rather, how that DNA functions.

1 Jul 2011

PENNSAID Viscous Solution Phase 2 clinical trial for osteoarthritis pain meets primary endpoint

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced receipt from Mallinckrodt Inc., a Covidien company (Covidien), of top-line results from a Phase 2 study conducted by Covidien, of twice-daily administration of PENNSAID Viscous Solution (topical diclofenac sodium viscous solution) 2% w/w, previously referred to as PENNSAID Gel.

30 Jun 2011

Lotus Tissue Repair to develop DEB protein replacement therapy with $26 million Series A financing

Lotus Tissue Repair, Inc. today announced the closing of a $26 million Series A financing led by Third Rock Ventures. Proceeds of the financing will be used to advance the company's proprietary recombinant collagen type VII (rC7) technology as the first and only protein replacement therapy in development for the treatment of dystrophic epidermolysis bullosa (DEB), an orphan disease that causes devastating skin blisters, morbidity and early mortality.

30 Jun 2011

Valeant to acquire rights relating to Elidel and Xerese from Meda

Valeant Pharmaceuticals International, Inc. announced today that its subsidiary, Valeant International SRL (VIB), has signed an agreement to acquire rights to both Elidel and Xerese from Meda, an international specialty pharmaceutical company for the U.S., Canada and Mexico.

30 Jun 2011

Valeant, Meda partner for life cycle opportunities for Elidel and Xerese

Meda and Valeant have entered into a collaboration agreement. Meda has out-licensed exclusive rights for Elidel and Xerese to Valeant for the U.S., Canada and Mexico. The parties will collaborate on life cycle opportunities for both products.

30 Jun 2011

Diagnostic delay in women with tuberous sclerosis complex increases mortality risk

Women with tuberous sclerosis complex (TSC) are often misdiagnosed because the condition, commonly recognized in early childhood when it presents with seizures, manifests differently later in life, typically with renal angiomyolipomas - a benign tumor of the kidney - and pulmonary lymphangioleiomyomatosis (LAM) - a rare lung disease that affects almost exclusively women.

30 Jun 2011

Researchers develop way to uncover evolution of human cancer cells

A team of researchers led by scientists at the University of California, San Francisco has developed a way to uncover the evolution of human cancer cells, determining the order in which mutations emerge in them as they wend their way from a normal, healthy state into invasive, malignant masses.

30 Jun 2011

Provectus presents additional data on PV-10 at two separate melanoma conferences

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that data and study design features on PV-10 for metastatic melanoma were presented at two separate conferences.

30 Jun 2011

Suneva Medical receives Health Canada marketing approval for Bellafill

Suneva Medical, a privately-held aesthetic medical device company, today announced the expansion of its core aesthetics injectable business with approval from Health Canada to market Bellafill™, its long lasting dermal filler for nasolabial folds or smile line correction.

29 Jun 2011

Bayer Yakuhin seeks marketing authorization in Japan for EYLEA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application to the Ministry of Health, Labor and Welfare (MHLW) in Japan for marketing authorization for EYLEA, also known as VEGF Trap-Eye, for the treatment of the neovascular form of age-related macular degeneration (wet AMD).

29 Jun 2011

FDA clears Nuvo's IND for Lidocaine Spray formulation

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application filed May 27, 2011 for a novel topical Lidocaine Spray formulation (NRI-ANA), allowing for initiation of Phase 1 studies.

29 Jun 2011

Cocaine contaminated with livestock de-worming drug causes painful purpura

If the obvious reasons for avoiding recreational drug use aren't off-putting enough, physicians have yet another detrimental consequence to add to the list - crusty, purplish areas of dead skin that are extremely painful and can open the door to nasty infections.

24 Jun 2011

Potential new approach for treating myelofibrosis

A new study conducted by a team of researchers at Boston University School of Medicine (BUSM) sheds light on a possible new approach to treat the bone marrow disease known as myelofibrosis by inhibiting an enzyme that connects extracellular fibers.

24 Jun 2011

Reductions in obesity-related medical costs offset cost of gastric banding surgery within 2.25 years

Allergan, Inc. today announced a new study published in the peer-reviewed journal Surgery for Obesity and Related Diseases that found the cost of a gastric banding weight-loss surgery procedure, such as Allergan's LAP-BAND Adjustable Gastric Banding System, was offset by reductions in obesity-related medical costs within 2.25 years for surgery eligible patients with diabetes, and within four years of the procedure for all surgery eligible patients.

23 Jun 2011

MEDA seeks marketing authorization for Zyclara in Europe

“Zyclara will strengthen Meda's dermatology franchise in Europe. We look forward to provide AK patients with a new product that can treat larger areas of the skin”

23 Jun 2011